Australia's Myer announced sweeping changes to its executive team on Friday, including picking rival David Jones' former CFO as finance chief, while the department store owner completes its merger ...

PMV Pharmaceuticals (PMVP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions ...

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and ...

PMV demonstrated excellent execution in 2024 with the continued advancement of the pivotal, Phase 2 portion of the PYNNACLE trial, and we look ...

“PMV demonstrated excellent execution in 2024 with the continued advancement of the pivotal, Phase 2 portion of the PYNNACLE trial, and we look forward to providing data from an interim analysis ...

Nos Sgps SA (FRA:PMV) reports robust financial performance with significant increases in revenue, EBITDA, and operational cash flow, while achieving nearly full 5G coverage.

This compares with -$68.96 million, or -$1.44 per share, last year. PMV Pharmaceuticals, Inc. earnings at a glance (GAAP) : -Earnings: -$58.71 Mln. vs. -$68.96 Mln. last year. -EPS: -$1.14 vs.

PMV Pharmaceuticals (NASDAQ:PMVP – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect PMV Pharmaceuticals to post ...

Mutations in the TP53 gene occur in approximately half of human cancer types, with the TP53 Y220C mutation found in 1% of all solid tumors. Researchers from PMV Pharmaceuticals Inc. and collaborators ...